Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Inhaled Medications01:23

Inhaled Medications

687
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
687
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

700
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
700
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.2K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial.

Respiratory research·2020
Same author

Simple non-mydriatic retinal photography is feasible and demonstrates retinal microvascular dilation in Chronic Obstructive Pulmonary Disease (COPD).

PloS one·2020
Same author

Chronic kidney disease, worsening renal function and outcomes in a heart failure community setting: A UK national study.

International journal of cardiology·2018
Same author

Consumer segmentation and time interval between types of hospital admission: a clinical linkage database study.

Journal of public health (Oxford, England)·2017
Same author

Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins.

International journal of clinical practice·2016
Same author

Long-term cognitive and school outcomes of late-preterm and early-term births: a systematic review.

Child: care, health and development·2016

Related Experiment Video

Updated: Jan 9, 2026

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
02:34

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms

Published on: May 10, 2024

1.8K

Inhaled beclomethasone versus placebo for chronic asthma.

N P Adams, J B Bestall, R Malouf

    The Cochrane Database of Systematic Reviews
    |January 28, 2005
    PubMed
    Summary

    Inhaled beclomethasone dipropionate (BDP) effectively treats chronic asthma, improving lung function and reducing symptom exacerbations. Both chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) formulations demonstrate significant benefits, though dose titration above 400 mcg/day shows limited support for mild to moderate cases.

    More Related Videos

    Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
    07:28

    Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

    Published on: April 6, 2017

    41.4K
    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
    14:39

    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

    Published on: November 4, 2010

    32.4K

    Related Experiment Videos

    Last Updated: Jan 9, 2026

    Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
    02:34

    Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms

    Published on: May 10, 2024

    1.8K
    Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
    07:28

    Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

    Published on: April 6, 2017

    41.4K
    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
    14:39

    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

    Published on: November 4, 2010

    32.4K

    Area of Science:

    • Pulmonology
    • Pharmacology

    Background:

    • Inhaled beclomethasone dipropionate (BDP) and budesonide are primary anti-inflammatory asthma therapies.
    • Newer asthma prophylactic treatments are emerging, and BDP has been reformulated with a hydrofluoroalkane-134a (HFA) propellant, replacing chlorofluorocarbon (CFC).

    Purpose of the Study:

    • Compare the efficacy of BDP (CFC and HFA propellants) against placebo in chronic asthma.
    • Investigate potential dose-response relationships for BDP in asthma treatment.
    • Establish BDP's efficacy as a benchmark for evaluating novel asthma therapies.

    Main Methods:

    • Systematic review of randomized controlled trials (RCTs) of at least four weeks duration.
    • Included trials compared CFC-BDP or HFA-BDP with placebo in pediatric and adult patients with chronic asthma.
    • Data extraction and quality assessment were performed independently by two reviewers.

    Main Results:

    • 60 studies with 6542 participants were analyzed.
    • CFC-BDP (≤400 mcg/day) significantly improved FEV1, PEF, reduced beta-2 agonist use, and decreased asthma exacerbation withdrawal risk.
    • HFA-BDP demonstrated significant efficacy in improving lung function, reducing symptoms, and beta-2 agonist use, with effects noted after six weeks.

    Conclusions:

    • The review confirms the efficacy of both CFC-BDP and HFA-BDP for chronic asthma management.
    • Published data offer limited support for dose titration above 400 mcg/day in mild to moderate asthma.
    • Insufficient data exist to determine dose-response relationships in severe asthma.